🚨 New Insights in HFpEF Therapy! 🫀🔬

A groundbreaking JACC: Basic to Translational Science study shows that hydrogen sulfide (H₂S) deficiency is not just a byproduct—but a central driver of cardiometabolic heart failure with preserved ejection fraction (HFpEF).

Using human plasma analysis + two robust preclinical models, researchers found:

⚠️ ~80–90% reduction in circulating H₂S

💔 Diastolic dysfunction, fibrosis, vascular impairment linked to low H₂S

💊 H₂S donors (JK-1, DATS) improved heart, liver, and vascular health

🤝 Synergy with Survodutide (GLP-1/glucagon agonist) boosted metabolic & cardiac outcomes

Why it matters: HFpEF is a multisystem syndrome—this study highlights a multi-target approach that restores redox balance, improves exercise capacity, and tackles metabolic drivers.

💡 Could H₂S-based combination therapies be the next frontier in HFpEF care?

#Cardiology #HFpEF #HydrogenSulfide #GLP1 #MetabolicTherapy #TranslationalResearch #HeartFailure #PrecisionMedicine #RedoxBiology #JACC